Taryag Medical

What Taryag Medical does

Taryag Medical Ltd. is an Israel-based, privately held medical device company founded in 2013 by Aharon (Arik) Cohen, operating as a subsidiary of Taryag Sterilization and Laboratories Services Ltd. The company develops and manufactures invasive vascular devices targeting peripheral vascular disease (PVD), with a single core commercial product — the BYCROSS® rotational atherectomy catheter.

The BYCROSS® device is a minimally invasive, single-use, fully disposable rotational atherectomy system featuring a bi-directional expandable a-traumatic tip (1.9–4.7mm) that rotates at 4750 RPM, coupled with a simultaneous non-clogging aspiration system that collects calcified atheroma and thrombus through an integrated battery-powered pump. Its central technical differentiator is non-occlusion-dependent operation: the device can treat chronic total occlusions (CTO) without requiring guidewire passage through the lesion first — a capability positioned as unique among rotational atherectomy competitors. Additional features include complete radiopacity for visualization, contrast medium injection capability, an embedded electronic malfunction detection system with automatic shutoff, and capital-equipment-free operation powered by disposable lithium batteries. The device is compatible with any guidewire ≤0.035" and targets femoropopliteal lesions, common femoral artery, external iliac, and below-the-knee vessels.

The business model is B2B direct sales of single-use hardware to hospitals, vascular surgery departments, and interventional radiology units. Pricing is undisclosed and negotiated via direct quotation and tender processes. Commercialization is currently EU-based, with clinical use established across multiple European territories (including Israel, the Netherlands via Angiocare, and sites such as Rabin Medical Center and Herzelia Medical Center). The company relies on peer-reviewed publications, KOL endorsements, conference presentations, and physician-led case studies as primary demand-generation channels. Clinical evidence includes a prospective pre-market approval study (NCT03724279, 39 patients / 41 femorodistal lesions, 6-month follow-up). The company has 1–10 employees, no disclosed institutional funding rounds, and expansion to additional territories is stated as planned.

Name

Taryag Medical

Legal name

Taryag Medical Ltd.

Website

https://taryag-medical.com

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

1–10 employees

Short description

Taryag Medical Ltd. is an Israel-based privately held medical device company that develops and sells the BYCROSS® rotational atherectomy catheter, a single-use disposable device for treating peripheral vascular disease and chronic total occlusions. The company sells directly to hospitals and vascular surgery centers, primarily in the EU, with expansion to additional territories planned.

Ownership category

akta.pro rank

Product category

Peripheral Vascular Devices (Atherectomy Catheters)

NAICS

Surgical and Medical Instrument Manufacturing (339112)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Open & Minimally Invasive Surgical Instruments (Handheld, Laparoscopic, MIS) (HLAHADAA)

Keywords

• Atherectomy catheters
• Vascular intervention devices
• Peripheral vascular devices
• Medical device manufacturing
• Rotational atherectomy systems

Headquarters

HQ city

Or Akiva

HQ country

Israel

HQ region

Middle East

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales

Revenue model

1. BYCROSS® Device Sales: Taryag Medical generates revenue through the sale of its BYCROSS® rotational atherectomy device and consumables. The device is a single-use, fully disposable system used in peripheral vascular interventions. Revenue is derived from direct sales to hospitals and medical facilities.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Core offering

Taryag Medical develops and manufactures the BYCROSS® rotational atherectomy catheter, a minimally invasive, single-use, fully disposable device for endovascular revascularization of peripheral arteries. The device features an expandable a-traumatic tip and simultaneous non-clogging aspiration system that enables treatment of chronic total occlusions where guidewire passage is not possible, providing an alternative to bypass surgery or amputation. The company sells directly to hospitals and vascular surgery centers.

Product overview

Taryag Medical offers a single core product, the BYCROSS® system, which is an advanced peripheral vascular disease (PVD) therapeutic system designed for endovascular revascularization of peripheral arteries. The BYCROSS® is a rotational atherectomy catheter with an expandable a-traumatic tip that incorporates a simultaneous non-clogging aspiration system for the collection of calcified material, enabling physicians to treat completely blocked occlusions where guidewire passage cannot be facilitated, as an alternative to bypass surgery or amputation.

Differentiator

Problem solved

Functional benefit

Brands

• BYCROSS®: A minimally invasive, single-use, fully disposable rotational atherectomy device with an expandable a-traumatic tip and simultaneous non-clogging aspiration system for treatment of peripheral vascular disease including chronic total occlusions.

Products and services

• BYCROSS® Rotational Atherectomy Catheter

Quantifiable outcome

• 39 patients with 41 femorodistal lesions treated successfully in pre-market approval study with 6-month follow-up

Named customers3 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

One partnership is on record.

• Taryag Sterilization and Laboratories Services Ltd.coreStrategic or Co-development Partner · 1 January 2015Taryag Medical Ltd. is a subsidiary of Taryag Sterilization and Laboratories Services Ltd. Taryag Sterilization provides comprehensive medical product development infrastructure including sterilization services, laboratory testing, and regulatory support. This parent company offers medical device innovators optimal infrastructure for rapid market entry while reducing costs and barriers. The relationship enables Taryag Medical to leverage shared resources and expertise across the medical device development lifecycle.

Scale indicators3 records

Recent moves5 records

Expansion highlights5 records

Emerging players

• AngioDynamics: Peripheral thrombectomy and venous portfolio (AlphaVac, AngioJet) overlaps with BYCROSS®'s aspiration-and-mechanical-debulking approach in peripheral vascular indications.

Broad incumbents

• Abbott Vascular: Post-CSI acquisition, Abbott is the dominant player in peripheral atherectomy (Diamondback 360, Stealth 360) and competes against BYCROSS® with deeper clinical data and a global salesforce.
• Philips (Image-Guided Therapy): Sells laser atherectomy (Phoenix) and interventional imaging systems used in peripheral vascular procedures; competes with BYCROSS® both as a device alternative and as a procedural ecosystem incumbent.
• Medtronic: Operates one of the largest peripheral vascular device portfolios globally, including atherectomy and thrombectomy solutions; competes indirectly via scale, clinical evidence, and integrated selling.
• Terumo Interventional Systems: Major peripheral vascular access and intervention portfolio including guidewires, catheters, and drug-coated technologies—competes indirectly via bundled procedural solutions and global distribution.
• Boston Scientific: Major peripheral vascular franchise including Rotational Atherectomy (Rotarex) and broad portfolio of balloons, stents, and imaging—competes with Taryag across the PVD treatment pathway via scale and bundled offerings.
• BD (Bard Peripheral Vascular): Legacy Bard peripheral vascular business now under BD, offering balloons, stents, and atherectomy-adjacent devices; competes for hospital contracts and procedural share alongside BYCROSS®.

Direct peers

• Penumbra: Maker of the Indigo® aspiration thrombectomy system for peripheral and coronary vessels, directly comparable to BYCROSS®'s simultaneous aspiration + mechanical debulking concept for thrombus and atheroma.
• Avinger: Developer of Pantheris image-guided atherectomy and Tigereye CTO-crossing devices for PAD; competes head-to-head with BYCROSS® in the peripheral atherectomy niche with an overlapping CTO capability angle.
• Cardiovascular Systems Inc. (CSI / Abbott): Maker of the Diamondback 360® orbital atherectomy system for peripheral arterial disease—the most direct competitor to BYCROSS® in the PVD atherectomy category, now part of Abbott's vascular portfolio.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/taryag-medical

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Taryag Medical